ARS Pharmaceuticals, Inc.SPRYNASDAQ
Loading
Operating Expenses Over TimeExpanding
Percentile Rank100
3Y CAGR+87.6%
5Y CAGR+124.8%
Year-over-Year Change
Expenses from normal business operations (SG&A, R&D, etc.)
3Y CAGR
+87.6%/yr
vs +21.5%/yr prior
5Y CAGR
+124.8%/yr
Recent deceleration
Acceleration
+66.1pp
Accelerating
Percentile
P100
Near historical high
vs 5Y Ago
57.5x
Strong expansion
Streak
5 yr
Consecutive growthExpanding
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $243.30M | +239.5% |
| 2024 | $71.67M | +6.1% |
| 2023 | $67.55M | +83.4% |
| 2022 | $36.83M | +48.8% |
| 2021 | $24.75M | +484.5% |
| 2020 | $4.23M | -81.2% |
| 2019 | $22.52M | +33.3% |
| 2018 | $16.90M | - |